2273-40-7

Usage

Uses

Used in Organic Synthesis:
2-(dimethylamino)-2-methylpropanenitrile is used as a reagent in organic synthesis for its high reactivity, facilitating the formation of complex organic molecules.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, DMAPN is utilized as a reagent and catalyst in the synthesis of various pharmaceuticals, contributing to the development of new drugs.
Used in Agrochemical Production:
2-(dimethylamino)-2-methylpropanenitrile is employed in the production of agrochemicals, where its reactivity aids in the synthesis of compounds used in agriculture to protect crops.
Used in Specialty Chemicals Synthesis:
DMAPN is used as a versatile building block in the synthesis of specialty chemicals, taking advantage of its unique chemical properties to create tailored products for specific applications.

Upstream product

• 74-90-8 hydrogen cyanide 
• 124-40-3 dimethyl amine 
• 67-64-1 acetone 
• 151-50-8 potassium cyanide 
• 506-59-2 N,N-dimethylammonium chloride 
• 7677-24-9 trimethylsilyl cyanide 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 4075-96-1 1-phenyl-2-dimethylaminopropane 
• 938-04-5 [1-(dimethylamino)-1-methylethyl]benzene 
• 76936-44-2 N²,N²-dimethyl-2-methyl-1,2-propanediamine 
• 52486-76-7 2-methyl-1-phenyl-2-dimethylaminopropan-1-one 
• 834915-92-3 3-[6-(2-dimethylamino-1-imidazol-1-yl-2-methyl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid 
• 1204-34-8 (2-amino-1,1-dimethyl-2-phenylethyl)dimethylamine 
• 201410-24-4 N-[4-[2-(dimethylamino)-2-methyl-1-oxopropyl]phenyl]acetamide 
• 52486-75-6 1-Phenyl-2-methyl-2-(dimethylamino)-propanol 
• 996-35-0 N,N-dimethylisopropyl amine 
• 42419-43-2 α-(p-bromophenylamino)isobutyronitrile 
• 6281-50-1 2-cyano-2-cyclohexylaminopropane 
• 42419-42-1 2-Heptylamino-2-methyl-propionitrile 

Relevant academic research and scientific papers

2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

A compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER

The invention provides compounds of formula I: wherein A, B, X, and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds, processes for preparing such compounds, and therapeutic methods fo

2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES

The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. Formula (I) wherein R1 is a group selected from: Formulas (A), (B), (C)

NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF

Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2). [wherein X is -CH2-, -O-, -S- or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R1 and R2 are (i) each is hydrogen or lower alkyl; (ii) R1 and R2 are combined to form lower alkylene; or (iii) R1 is hydrogen or lower alkyl and R2 is combined with R4 or R6 to form lower alkylene; R3 and R4 are (i) each is hydrogen or lower alkyl; (ii) R3 and R4 are combined to form lower alkylene; or (iii) R3 is hydrogen or lower alkyl and R4 is combined with R2 or R6 to form lower alkylene; R is or -OR7; R 5 and R6 are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R5 and R6 are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R5 is optionally substituted lower alkyl or hydrogen and R6 is combined with R2 or R4 to form lower alkylene; R7 is lower alkyl.

Serotoninergic properties of new conformationally restricted benzamides

A new series of benzamides derived from metoclopramide have been synthesized, in which the vicinal carbon of the basic nitrogen atom of the ethyl chain is situated on the C3, C4, C5 and C6 rings. The diamino derivatives were prepared through Strecker's reaction from the corresponding ketones except for the cyclopropyl derivatives where 1-ethoxy-1-trimethylsiloxy cyclopropane was used as the starting material. The benzamides were prepared using the mixed anhydride method. They were tested in binding assays for D2, 5-HT3 and 5-HT4 receptors. The results show a marked increase in the selectivity and potency of these derivatives for 5-HT3 receptors with regard to metoclopramide (compound 1d: 5-HT3 K(i) = 9.03 nM; 5-HT4 K(i) > 5000; D2 K(i) > 5000). The influences of steric hindrance and hydrophobic properties on the affinity of benzamide derivatives for 5-HT3 receptors were also emphasized by these data. The X-ray crystal structure of compound 1d was compared with that of the minimal energy conformer of BRL 24682, a reference 5-HT3 receptor antagonist benzamide, determined using the Random Search program. Superimposition of the two structures showed a suitable fit between the pharmacophore groups previously determined to be important for 5-HT3 receptor antagonists. On the other hand, the hydrophobic parts of the basic moieties had different spatial occupancies.

A FAST N-SUBSTITUTED α-AMINONITRILE SYNTHESIS

A series of α-aminonitriles bearing various functionalities was prepared by reacting a neat mixture of an aldehyde or ketone, an amine and trimethylsilyl cyanide.The reaction was essentially complete in 5 minutes.